Loading clinical trials...

COMPLETEDNA

Lipid-Lowering Effect and Hypotensive Effect of Shanzha Fruit Drink in Patients

A Randomized, Double-Blind, Placebo-Controlled Cross-Over Study to Evaluate the Safety, Lipid-Lowering Effect and Hypotensive Effect of Shanzha Fruit Drink in Patients With Mild to Moderate Hyperlipidemia

NCT04672278•Chinese University of Hong Kong

View on ClinicalTrials.gov

Summary

This is a single-center, randomized, double-blind, placebo-controlled, cross-over study. Subjects who meet the inclusion/exclusion criteria will be randomly and alternatively assigned to receive Shanzha fruit drink or placebo drink in the first 2 months or the last two months of the 5 months study period. In between the first and second treatment period, all patients will enter a Washout Period of 4 weeks and during which time patients should not receive any of the study functional fruit drink.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•• Total Cholesterol between 200-300 mg/dl (5.2-7.8 mmol/l).
•* Mean plasma triglyceride \>= 4.5 mmol/l.
•* Diastolic blood pressure 95-100 mm Hg and/or Systolic blood pressure 130-150 mm Hg.
•* Be able to give written informed consent prior to study start and comply with study requirements.

Exclusion Criteria

•• Total Cholesterol between 200-300 mg/dl (5.2-7.8 mmol/l).
•* Mean plasma triglyceride \< 4.5 mmol/l.
•* Diastolic blood pressure 95-100 mm Hg and/or Systolic blood pressure 130-150 mm Hg.
•* Be able to give written informed consent prior to study start and comply with study requirements.

Locations (1)

The Chinese University of Hong Kong

Hong Kong, Hong Kong

Key Dates

Start Date

January 2, 2019

Primary Completion Date

October 30, 2020

Completion Date

October 30, 2020

Last Updated

April 23, 2021

Enrollment

ACTUAL participants

Conditions

HyperlipidemiaHypertension

Interventions

Shanzha Fruit drink or placebo drink

DIETARY_SUPPLEMENT

Natural History of Noncirrhotic Portal Hypertension

NCT02417740

Cystic FibrosisImmunologic Deficiency Syndrome+3 more

View study

RECRUITINGPHASE2

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

NCT07073820

Pulmonary Hypertension

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 23, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Lipid-Lowering Effect and Hypotensive Effect of Shanzha Fruit Drink in Patients

Inclusion Criteria

Exclusion Criteria

Natural History of Noncirrhotic Portal Hypertension

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension

Mobile Cued Adherence Therapy (mCAT) for Blood Pressure Medication

Penn Medicine Healthy Heart

Preliminary Human Trials of F230 Tablets